{"nctId":"NCT02752880","briefTitle":"YH1 in Poorly Controlled Type 2 Diabetes","startDateStruct":{"date":"2016-06","type":"ACTUAL"},"conditions":["Type 2 Diabetes"],"count":46,"armGroups":[{"label":"YH1 group","type":"EXPERIMENTAL","interventionNames":["Drug: YH1 group"]},{"label":"placebo group","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo group"]}],"interventions":[{"name":"YH1 group","otherNames":["Rhizoma Coptidis and Shen-Ling-Bai-Zhu-San"]},{"name":"placebo group","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. 20-75 years of age;\n2. Diagnosed as type 2 diabetics based on World Health Organization criteria \\[1\\];\n3. Body mass index (BMI) ≥ 23 kg/m2;\n4. Have been treated with ≥ 3 kinds of oral hypoglycemic agents (OHAs) with persistent (\\> 6 months) high HbA1c (≥ 7.0 %).\n\nExclusion Criteria:\n\n1. Type 1 diabetes, gestational diabetes, or other specific types of diabetes;\n2. Have received insulin therapy in the past three months;\n3. Have serious gastrointestinal (GI) tract diseases, such as peptic ulcers or GI tract bleeding;\n4. Experience stressful situations, including diabetic ketoacidosis, nonketotic hyperosmolar diabetic coma, severe infection, or surgery in the previous one month;\n5. Suffer from hepatic insufficiency with alanine aminotransferase (ALT) 2 times the upper limit of normal or renal insufficiency with estimated glomerular filtration rate (eGFR) \\< 60;\n6. Uncontrolled hypertension (blood pressure ≥ 160/100 mmHg);\n7. Mental illness, abused or addicted to alcohol, psychoactive substances or other drugs;\n8. Pregnant, lactating, or plan to become pregnant;\n9. Hemoglobin disease or chronic anemia;\n10. Have underlying conditions that could lead to poor compliance;\n11. History of cerebrovascular disease or myocardial infarction;\n12. Have undergone Chinese medicine treatment in the past two weeks.","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Percentage Change in HbA1c Level From Baseline to 12 Weeks","description":"The primary efﬁcacy endpoint was the percentage change in HbA1c levels from baseline to 12 weeks. The HbA1c level was measured by HPLC in the Department of Laboratory Medicine at Chang Gung Memorial Hospital.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.1","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"The Percentage Change in 2hPG From Baseline to Week 12","description":"The secondary efﬁcacy endpoint was the percentage change in 2hPG level from baseline to 12 weeks by using enzymatic method in the Department of Laboratory Medicine at Chang Gung Memorial Hospital.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-26.2","spread":null},{"groupId":"OG001","value":"5.1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":23},"commonTop":["diarrhea","upper respiratory tract infection","abdominal fullness","nausea","dizziness"]}}}